多西他赛联合奥沙利铂治疗晚期胃癌的临床观察  

Clinical Observation of Docetaxel Combined with Oxaliplatin Regimen for Advanced Gastric Cancer

作　　者：韩轶超[1] 彭晔[1] 杨秀芳[1] 谢娜[1] 

机构地区：[1]衡水市哈励逊国际和平医院肿瘤内科,河北衡水053000

出　　处：《华西医学》2014年第11期2055-2058,共4页West China Medical Journal

摘　　要：目的观察多西他赛联合奥沙利铂治疗晚期胃癌的有效性和安全性。方法将肿瘤内科2008年1月-2011年1月收治的60例晚期胃癌患者随机分为2组。治疗组30例,给予多西他赛75 mg/m2静脉滴注,第1天用药;奥沙利铂130 mg/m2静脉滴注,第4天用药;21 d为1个周期。对照组30例,给予多西他赛75 mg/m2静脉滴注,第1天用药,顺铂75 mg/m2静脉滴注,第1天用药;亚叶酸钙200 mg/m2静脉输注2 h,第1~2天用药;后氟尿嘧啶400 mg/m2静脉推注10 min及氟尿嘧啶600 mg/m2持续静脉泵入22 h,第1~2天用药,21 d为1个周期。所有患者至少接受2个周期化学疗法（化疗）。观察两组的有效率、不良反应、中位生存期及生活质量的改善。结果治疗组与对照组有效率分别为60.0%、46.7%,差异无统计学意义（P〉0.05）;治疗组食欲增加率（治疗组70.0%、对照组43.3%）、体质量增加率（治疗组60.0%、对照组33.3%）及Karnofsky评分好转率（治疗组63.3%、对照组30.0%）均优于对照组,两组比较差异有统计学意义（P〈0.05）。治疗组不良反应较轻,大部分为Ⅰ~Ⅱ度,优于对照组。治疗组与对照组中位疾病进展时间分别为5.8、5.6个月,中位生存期分别为11.8、9.2个月,较对照组延长。结论多西他赛联合奥沙利铂治疗晚期胃癌疗效确切,不良反应轻,患者耐受性好,生活质量明显提高,中位生存期延长,值得临床推广。Objective To evaluate the efficacy and safety of docetaxel（DOC） combined with oxaliplatin（OXA） regimen in the treatment of advanced gastric cancer. Methods Sixty patients with advanced gastric cancer treated in our hospital from January 2008 to January 2011 were randomly divided into two groups. The treatment group（n=30） was given DOC combined with OXA regimen. Patients in this group were treated with DOC 75 mg/m2, ivgtt, d1; OXA 130 mg/m2, ivgtt, d4; with 21 days as a cycle. The control group（n=30） was given DCF regimen. Patients in the control group were treated with DOC 75 mg/m2, ivgtt, d1; cisplatin 75 mg/m2, ivgtt, d1; calcium folinate 200/m2, ivgtt, 2 h, d1-2; fluorouracil 400 mg/m2, bolus 10 minutes, fluorouracil 600 mg/m2 civ 22 h d1-2; also with 21 days as a cycle. All patients received two cycles of chemotherapy at least. The effective rate（complete remission＋partial remission）, adverse reactions, median survival time and quality of life were analyzed and compared between the two groups. Results The effective rates in the treatment group and the control group were 60.0% and 46.7% respectively, showing a non-significant difference（P 〉 0.05）. The appetite increasing rate（70.0% vs 43.3%）, the weight gain rate（60.0% vs 33.3%）, and the Karnofsky score improvement rate（63.3% vs 30.0%） of the treatment group were significantly higher than those of the control group（P 〈 0.05）. The adverse reactions were fewer in the treatment group, and most of them were between grade Ⅰ and Ⅱ. The median time of disease progression（5.8 months vs 5.6 months） and the median survival period（11.8 months vs 9.2 months） of the treatment group were longer than those in the control group. Conclusions DOC combined with OXA regimen is effective in treating advanced gastric cancer. It can significantly improve the quality of life of the patients, and it has fewer adverse reactions. Meanwhile, the median survival period is prolonged. DOC combined with OXA regimen is worth to be appl

关 键 词：多西他赛 奥沙利铂 化学疗法 晚期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]